Working… Menu
Trial record 22 of 88 for:    "Neuromuscular Disease" | "Norepinephrine"

Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01418651
Recruitment Status : Terminated (Lack of subjects)
First Posted : August 17, 2011
Last Update Posted : August 17, 2011
Forest Laboratories
Information provided by:
Banner Health

Brief Summary:
Participants will undertake a 12-week, open-label study of milnacipran in a well-characterized cohort of patients with fibromyalgia syndrome (FMS) who are 65 years and older to investigate the short-term efficacy and safety of this drug in the elderly population. The investigators hypothesize that milnacipran will be effective in treating fibromyalgia syndrome (FMS), and will be prove to be safe when patients are selected for the absence of pre-existing blood pressure abnormalities and other serious medical conditions.

Condition or disease Intervention/treatment Phase
Fibromyalgia Drug: Savella Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population: an Open-label Study
Study Start Date : March 2011
Estimated Primary Completion Date : August 2011
Estimated Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fibromyalgia

Arm Intervention/treatment
Experimental: Milnacipran
Drug: Savella
milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)

Primary Outcome Measures :
  1. Change in self-reported severity of pain over 12 weeks of treatment in persons aged 65 and older [ Time Frame: 14 months ]

    Percent change in self-reported severity of pain (averaged Visual Analog Scale scores) over 12 weeks of treatment.

    Rate of occurrence of adverse events necessitating drug discontinuation

Secondary Outcome Measures :
  1. Determine the effects of milnacipran on cognition [ Time Frame: 14 months ]

    Change in functional activity (FIQ), perceived health (SF-36), and severity of pain (Gracely scale).

    Incidence and severity of treatment-emergent adverse events. Change in sleep quality and daytime sleepiness as measured by the Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale.

    Change in other sleep/wake parameters(actigraphy measures). Change in cognitive test scores from baseline to the 12 week visit. Patient global impression of change score.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients.
  • Age 65 years or older.
  • Fibromyalgia diagnosed according to ACR 1990 criteria.
  • Pain Score ≥ 10 on Gracely scale at screening and baseline assessments.
  • Discontinuation of other dual-acting antidepressant medications, including duloxetine, venlafaxine, and tricyclic antidepressants for a period not less than 4.5 times the drug half-life as of the baseline evaluation.

Exclusion Criteria:

  • Uncontrolled hypertension (BP ≥ 140/90) at screening or baseline evaluations.
  • Baseline orthostasis (documented drop in SBP ≥ 20 mmHg or in DBP ≥ 10 mmHg within 3 minutes after standing) at screening or baseline evaluations.
  • Psychosis, active suicidality, current episode of major depression or other severe psychiatric illness, or current alcohol/substance abuse or dependence as assessed by the MINI.
  • Significant cardiovascular disease, including atrial fibrillation or other dysrhythmia, congestive heart failure, valvular heart disease, or QTc prolongation on baseline EKG (> 450 msec).
  • Uncontrolled narrow angle glaucoma.
  • History of seizures.
  • Use of MAO inhibitor drugs within the last 14 days.
  • Abnormal baseline liver or renal function tests.
  • Dementia or other syndrome of cognitive impairment that could interfere with the subject's ability to participate fully in the assessment protocol.
  • Obstructive uropathy in males.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01418651

Layout table for location information
United States, Arizona
Banner Sun Health Research Institute
Sun City, Arizona, United States, 85351
Sponsors and Collaborators
Banner Health
Forest Laboratories
Layout table for investigator information
Principal Investigator: Sandra Jacobson, MD Banner Health

Layout table for additonal information
Responsible Party: Sandra Jacobson MD - Research Physician, Banner Sun Health Research Inst. Identifier: NCT01418651     History of Changes
Other Study ID Numbers: 10-007
First Posted: August 17, 2011    Key Record Dates
Last Update Posted: August 17, 2011
Last Verified: January 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromuscular Diseases
Serotonin and Noradrenaline Reuptake Inhibitors
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Nervous System Diseases
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Antidepressive Agents
Psychotropic Drugs